America Pouchitis Treatment Market Research Report to 2023

$4450$6250

The pouchitis treatment market is segmented into North and South America. North America is estimated to reach USD 15.06 million by 2023.

Description

America Pouchitis Treatment Market

Pouchitis is a nonspecific inflammatory condition in the ileal pouch reservoir. It is a common complication following proctocolectomy and ileal pouch-anal anastomosis.

The condition exclusively occurs in patients with underlying Ulcerative Colitis (UC) and is rarely seen in patients with Familial Adenomatous Polyposis (FAP). Patients with UC or FAP opt for the Ileal Pouch-Anal Anastomosis (IPAA) surgery as a treatment and pouchitis appear as an outcome of this surgery in some cases.

On the basis of treatment, the Americas pouchitis treatment market is classified into antibiotics, probiotics, and others. The antibiotics segment held the largest market share in 2016.

On the basis of end-user, the Americas pouchitis treatment market is segmented into hospitals and clinics, research institutes, and others. In 2016, hospitals and clinics accounted for the largest share in the Americas pouchitis treatment market.

Regionally, the market is segmented into North America and South America. North America held the largest market share in 2016 and is estimated to reach USD 15.06 million by 2023.

Key Players

The key players in the Americas IBS treatment market are Allergan Plc, Sucampo Pharmaceuticals, Ironwood Pharmaceuticals, Inc., Astellas Pharma Inc., Valeant Pharmaceuticals, Abbott Laboratories, Synergy Pharmaceuticals, Inc., Ardelyx, Inc., Nestle, Sebela Pharmaceuticals, Probi, Alfasigma USA, Inc., and others.

Study objectives

• To provide insights into factors influencing and affecting the market growth
• To provide historical and forecast revenue of market segments and sub-segments with respect to countries
• To provide historical and forecast revenue of market segments based on treatment, end-user, and region.
• To provide strategic profiling of key players in the market and comprehensively analyze their market share, core competencies, and draw a competitive landscape for the market
• To provide economic factors that influence the Americas pouchitis treatment market
• To provide a detailed analysis of the value chain and supply chain of the Americas pouchitis treatment market
Target Audience
Pharmaceutical and Biotech Industries
• Potential Investors
• Medical Research Institutes
• Key Executive (CEO and COO) and Strategy Growth Managers
• Research Companies

Key Findings

• The major companies operating in the market are, Allergan Plc, Sucampo Pharmaceuticals, Ironwood Pharmaceuticals, Inc., Astellas Pharma Inc., Valeant Pharmaceuticals, and Abbott Laboratories, among others

• Antibiotics segment registered USD 8.94 million market revenue in the year 2016 and is expected to grow during the forecast period
• Hospitals and clinics are the fastest-growing segment, by end-user

Regional Analysis
Americas
• North America
o the U.S.
o Canada
• South America

Global Genomic Cancer Testing Market 2029

Bone And Joint Health Ingredient

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

1 Report Prologue 2 Market Introduction 2.1 Definition 2.2 Scope of the Study 2.3 List of Assumptions 2.4 Limitations 2.5 Market Structure 3 Research Methodology 3.1 Research Process 3.2 Primary Research 3.3 Secondary Research 3.4 Market Size Estimation 3.5 Forecast Model 4 Market Dynamics 4.1 Introduction 4.2 Drivers 4.2.1 Growing Demand from key industries such as electronics & electrical and industrial manufacturing 4.2.2 Wide application scope of silicon carbide ceramic 4.2.3 Excellent properties associated with silicon carbide ceramic 4.3 Restraints 4.3.1 High cost associated with silicon carbide ceramics 4.4 Opportunities 4.4.1 Substantial demand from niche markets 4.4.2 Massive steel manufacturing 4.5 Challenges 4.5.1 Increasing competition from silicon carbide substitute 5 Market Factor Analysis 5.1 Supply Chain Analysis 5.1.1 Raw material suppliers 5.1.2 Silicon carbide ceramics manufacturers 5.1.3 Distribution channel 5.1.4 End-use industries 5.2 Porter’s Five Forces Model 5.2.1 Competitive rivalry 5.2.2 Threat of new entrants 5.2.3 Threat of substitute 5.2.4 Bargaining power of supplier 5.2.5 Bargaining power of consumers 5.3 Supplier & Distributors Analysis 5.3.1 Introduction 5.4 Manufacturing Cost Analysis 5.4.1 Introduction 5.4.2 Fixed Cost 5.4.3 Raw material Cost 5.4.4 Energy Cost 5.5 Technical Data Analysis 5.5.1 Technical Data of Silicon Carbide Ceramics 6 Global Silicon carbide ceramics Market, By Type 6.1 Introduction 6.2 Pressure Sintered 6.3 Reaction Bonded 6.4 Recrystallized Silicon carbide 7 Global Silicon carbide ceramics Market, By Application 7.1 Introduction 7.2 Electrical & Electronics 7.3 Automotive 7.4 Machinery Manufacturing (Cutting tolls & wear parts) 7.5 Metallurgic 7.6 Aerospace & Defense 7.7 Metal Mining 7.8 Industrial 7.9 Others 8 Global Silicon carbide ceramics Market, By Region 8.1 Introduction 8.2 North America 8.2.1 The U.S. 8.2.2 Canada 8.3 Europe 8.3.1 Germany 8.3.2 UK 8.3.3 Russia 8.3.4 Belgium 8.3.5 France 8.3.6 Spain 8.3.7 Rest of the Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 India 8.4.3 Japan 8.4.4 South Korea 8.4.5 Rest of the Asia Pacific 8.5 Latin America 8.5.1 Brazil 8.5.2 Mexico 8.5.3 Argentina 8.5.4 Rest of the Latin America 8.6 Middle East & Africa 8.6.1 UAE 8.6.2 Turkey 8.6.3 Saudi Arabia 8.6.4 Rest of the Middle East & Africa 9 Competitive Landscape 9.1 Introduction 9.2 Market Strategy Overview 9.3 Consumer Analysis 9.4 Introduction 10 Company Profiles 10.1 Saint-Gobain 10.1.1 Company Overview 10.1.2 Financials 10.1.3 Products 10.1.4 Strategy 10.1.5 Key Developments 10.1.6 SWOT Analysis 10.2 CeramTec 10.2.1 Company Overview 10.2.2 Financials 10.2.3 Products 10.2.4 Strategy 10.2.5 Key Developments 10.2.6 SWOT Analysis 10.3 Morgan Advanced Materials 10.3.1 Company Overview 10.3.2 Financials 10.3.3 Products 10.3.4 Strategy 10.3.5 Key Developments 10.3.6 SWOT Analysis 10.4 Ortech Advanced Ceramics 10.4.1 Company Overview 10.4.2 Financials